Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Year: 2002
Type: article
Abstract: sued an advisory on Nov. 30, 2001,1 af-ter receiving an increasing number of reports of congestive heart failure (CHF), pulmonary edema and pleural effusion suspected to be associated with the diabetic agents rosiglitazone and pioglitazone. Letters to health profes-sionals were also issued by the respec-tive manufacturers, GlaxoSmithKline and Eli Lilly Canada.2,3
Source: PubMed Central
Author: Eric Wooltorton
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1933512009